Allianz Asset Management
NERV icon

Allianz Asset Management’s Minerva Neurosciences NERV Stock Holding History

Allianz Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,244
Closed -$204K – 2738
2019
Q1 		$204K Sell
3,244
-74
-2% -$4.45K ﹤0.01% 2584
2018
Q4 		$179K Buy
+3,318
New +$243K ﹤0.01% 2536

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allianz Asset Management's NERV Position: Q2 2019 in Review

Allianz Asset Management sold out of Minerva Neurosciences (NERV) in Q2 2019, closing a stake of 3,244 shares — an estimated $204K sold.

Allianz Asset Management first reported a position in NERV in Q4 2018 and held it in 2 quarters. The position peaked at $204K in Q1 2019. 85 funds tracked by Wall St. Rank hold NERV as of Q2 2019.

  • Allianz Asset Management reported no remaining Minerva Neurosciences position as of Q2 2019 after selling out during the quarter.
  • Allianz Asset Management sold 3,244 Minerva Neurosciences shares in Q2 2019, an estimated $204K.
  • Allianz Asset Management first reported a position in Minerva Neurosciences in Q4 2018 and held it in 2 quarters.
  • Allianz Asset Management's Minerva Neurosciences position peaked at $204K in Q1 2019.
  • 85 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2019.

Based on Allianz Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.